The tumour sink effect on the biodistribution of 68Ga-DOTA- octreotate: Implications for peptide receptor radionuclide therapy

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 1, 2012, Pages 50-56

  Beauregard, Jean Mathieu ^a,b   Hofman, Michael S ^a   Kong, Grace ^a   Hicks, Rodney J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

68GA DOTA octreotate; Biodistribution; Dosimetry; Neuroendocrine tumour; Peptide receptor radionuclide therapy; PET CT; Somatostatin receptor

Indexed keywords

RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR; TETRAXETAN OCTREOTATE GA 68; UNCLASSIFIED DRUG; 68GA DOTATATE; 68GA-DOTATATE; DIAGNOSTIC AGENT; ORGANOMETALLIC COMPOUND;

ADULT; AGED; ARTICLE; BODY SURFACE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL PROTOCOL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG UPTAKE; FEMALE; HUMAN; KIDNEY PARENCHYMA; KIDNEY TUBULE ABSORPTION; LEAN BODY WEIGHT; MALE; NEUROENDOCRINE TUMOR; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; RADIATION DOSE; RADIOISOTOPE THERAPY; SOFT TISSUE; SPLEEN; URINARY EXCRETION; INJECTION; METABOLISM; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; SCINTISCANNING; STATISTICAL MODEL;

ADULT; AGED; FEMALE; HUMANS; INJECTIONS; LINEAR MODELS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, SOMATOSTATIN; RETROSPECTIVE STUDIES;

EID: 84858737611     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1937-3     Document Type: Article

References (20)

1. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124-30.
2. Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, et al. [177Lu-DOTA0Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med 2001;28:1319-25.
3. Sandström M, Garske U, Granberg D, Sundin A, Lundqvist H. Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate. Eur J Nucl Med Mol Imaging 2010;37:212-25.
4. Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging 2008;35:1847-56.
5. Beauregard JM, Hicks RJ. Comparison of neuroendocrine tumor lesions uptake on Ga-68-octreotate-PET/CT and posttherapy Lu-177-octreotate-SPECT/CT [abstract]. J Nucl Med 2009;50:S1657.
6. Prasad V, Baum RP. Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions. Q J Nucl Med Mol Imaging 2010;54:61-7.
7. Boy C, Heusner TA, Poeppel TD, Redmann-Bischofs A, Unger N, Jentzen W, et al. (68)Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUV(max). Eur J Nucl Med Mol Imaging 2011;38:1224-36.
8. Kaemmerer D, Peter L, Lupp A, Schulz S, Sänger J, Prasad V, et al. Molecular imaging with (68)Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2011;38:1659-68.
9. Hallynck TH, Soep HH, Thomis JA, Boelaert J, Daneels R, Dettli L. Should clearance be normalised to body surface or to lean body mass? Br J Clin Pharmacol 1981;11:523-6. (Pubitemid 11150198)
10. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med 1987;317:1098.
11. Zhernosekov KP, Filosofov DV, Baum RP, Aschoff P, Bihl H, Razbash AA, et al. Processing of generator-produced 68Ga for medical application. J Nucl Med 2007;48:1741-8. (Pubitemid 47572722)
12. Kim DW, Kim CG, Park SA, Jung SA, Yang SH. Metabolic super scan in F-FDG PET/CT imaging. J Korean Med Sci 2010;25:1256-7.
13. Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273-82. (Pubitemid 30167697)
14. Lewis JS, Lewis MR, Cutler PD, Srinivasan A, Schmidt MA, Schwarz SW, et al. Radiotherapy and dosimetry of 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model. Clin Cancer Res 1999;5:3608-16.
15. Breeman WA, Kwekkeboom DJ, Kooij PP, Bakker WH, Hofland LJ, Visser TJ, et al. Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats. J Nucl Med 1995;36:623-7.
16. Beauregard JM, Hofman MS, Pereira JM, Eu P, Hicks RJ. Quantitative (177)Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system. Cancer Imaging 2011;11:56-66.
17. Wang Q, Graham K, Schauer T, Fietz T, Mohammed A, Liu X, et al. Pharmacological properties of hydrophilic and lipophilic derivatives of octreotate. Nucl Med Biol 2004;31:21-30. (Pubitemid 38115122)
18. Vegt E, de Jong M, Wetzels JF, Masereeuw R, Melis M, Oyen WJ, et al. Renal toxicity of radiolabeled peptides andantibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med 2010;51:1049-58.
19. Förster GJ, Engelbach MJ, Brockmann JJ, Reber HJ, Buchholz HG, Mäcke HR, et al. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTA-TOC and (111)In-DTPA-octreotide. Eur J Nucl Med 2001;28:1743-50.
20. Hubble D, Kong G, Michael M, Johnson V, Ramdave S, Hicks RJ. 177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide. Eur J Nucl Med Mol Imaging 2010;37:1869-75.